Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00013897
Status:
COMPLETED
Last Update Posted:
2011-05-04
First Post:
2001-03-31
Brief Title:
A Comparison of BMS-232632 With Efavirenz Each in Combination With Zidovudine-Lamivudine
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz Each in Combination With Fixed Dose Zidovudine-Lamivudine
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz EFV when both are used with zidovudine ZDV and lamivudine 3TC
Detailed Description:
This is a multinational 2-arm study Patients in 1 arm receive BMS-232632 plus EFV placebo capsules Patients in the other arm receive EFV plus BMS-232632 placebo Both arms also receive a fixed dose of ZDV-3TC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI424-034 | None | None | None |